Kiora Commences Mid-Stage Rare Eye Disease Study

Kiora Pharmaceuticals KPRX enrols the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with Persistent Corneal Epithelial Defect (PCED).

The Phase 2 clinical trial is designed as a single-arm, open label ten patient (up to 20 eyes) study, evaluating subjects 28 days after receiving KIO-201 six times daily.

The endpoints of the study include safety and tolerability︎, as well as the percentage of patients with corneal healing and the associated time to healing.

Brian M. Strem, President and Chief Executive Officer, Stated, “We believe KIO-201 has the potential to address a rare ophthalmic condition in patients who have limited effective treatment options. Promising results from this study will support our efforts to advance KIO-201 to a potential registration study.”

KIO-201 is a chemically modified form of the natural polymer hyaluronic acid, designed to accelerate natural corneal wound healing.

Price Action: Kiora shares are trading about 5 percent higher at $0.47 on Tuesday at the time of publication.

Posted In: Patient EnrolmentBiotechPenny StocksHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.